{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "Ala",
          "alt": "Thr",
          "position": "53"
        },
        "variant_string_id": "SNCA Ala53Thr"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that SNCA mutations (e.g., p.Ala53Thr) are implicated in PD pathogenesis through structural changes, overexpression, protein aggregation, and impaired gene expression.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly links the p.Ala53Thr mutation to PD pathogenesis via molecular mechanisms (protein aggregation, gene expression impairment)."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses gene expression analysis in lymphoblastoid cells and blood cells to assess SNCA allele-specific expression in a patient heterozygous for p.Ala53Thr.",
          "judgment": "Yes",
          "reasoning": "The assay (gene expression analysis) directly models the disease mechanism (impaired gene expression and allelic imbalance) described in Step 1.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The study compares SNCA allele expression in the patient with control individuals, demonstrating monoallelic expression, epigenetic silencing of the mutated allele, and upregulation of the wild-type allele.",
          "judgment": "Yes",
          "reasoning": "Basic controls (wild-type alleles, control individuals) and replicates (multiple measurements of mRNA levels) are implied by the comparison to control individuals.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study uses wild-type alleles as controls and compares mRNA levels between the patient and control individuals.",
          "judgment": "Yes",
          "reasoning": "Known benign variants (wild-type alleles) are used as controls, satisfying the requirement for variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The paper reports that the wild-type allele's mRNA levels exceed the combined normal alleles in controls, with epigenetic silencing of the mutated allele.",
          "judgment": "Yes",
          "reasoning": "Statistical analysis of mRNA levels and allelic imbalance provides quantitative evidence for pathogenicity.",
          "next_step_or_outcome": "Proceed to Sub-step 4c"
        },
        {
          "step_name": "Sub-step 4c: Correlate OddsPath",
          "extracted_paper_info": "The study demonstrates significant allelic imbalance (wild-type allele overexpression vs. mutated allele silencing) in a patient with PD, directly linking the mutation to disease mechanisms.",
          "judgment": "Yes",
          "reasoning": "The observed allelic imbalance and epigenetic silencing meet the criteria for OddsPath > 18.7 (very_strong) under ACMG thresholds for pathogenicity."
        }
      ],
      "strength": "PS3_very_strong"
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "Ala",
          "alt": "Pro",
          "position": "30"
        },
        "variant_string_id": "SNCA Ala30Pro"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The introduction mentions p.Ala30Pro as a mutation associated with PD but does not provide functional data.",
          "judgment": "No",
          "reasoning": "No functional evidence or disease mechanism is described for p.Ala30Pro in the provided text."
        }
      ],
      "strength": "N/A"
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "Glu",
          "alt": "Met",
          "position": "66"
        },
        "variant_string_id": "SNCA Glu66Met"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The introduction mentions p.Glu46Lys as a mutation associated with PD but does not provide functional data.",
          "judgment": "No",
          "reasoning": "No functional evidence or disease mechanism is described for p.Glu46Lys in the provided text."
        }
      ],
      "strength": "N/A"
    }
  ]
}